EQL Pharma AB (publ) (STO:EQL)

Market Cap	2.65B
Revenue (ttm)	373.52M
Net Income (ttm)	43.12M
Shares Out	29.06M
EPS (ttm)	1.44
PE Ratio	63.33
Forward PE	42.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,278
Average Volume	17,559
Open	91.80
Previous Close	91.80
Day's Range	90.10 - 92.50
52-Week Range	49.20 - 93.50
Beta	0.66
RSI	62.98
Earnings Date	Jul 28, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.